What is Epilepsy Phase 3 Study Retigabine IR?

Category: Others

false

See also: Clinical Trial

NCT01227902 is an open-label, flexible dose study of retigabine immediate release (IR) as adjunctive therapy to specified monotherapy antiepileptic treatments in adults with partial-onset seizures. Other study IDs include: 113905 and IR.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
1
Mild
0
None
1

Commonly reported side effects and conditions associated with Epilepsy Phase 3 Study Retigabine IR

Side effect Patients
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 2
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 0
Last updated:

1 patient evaluation for Epilepsy Phase 3 Study Retigabine IR

Jan 16, 2011 (Started Jan 09, 2000)

  • Effectiveness
    Major (for epilepsy)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 900 mg Daily
Advice & Tips: Seems I have more control over pain since I have been taking Retigabine. Retigabine is still waiting FDA approval, I look for it to be on the market and helping others soon.
Cost: < $25 monthly

Aug 20, 2010 (Started Jan 09, 2000)

  • Effectiveness
    Major (for epilepsy)
  • Side effects
    Moderate
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 900 mg Daily
Advice & Tips: Side effects are experienced after each dosage, even years after taking the med. Positive effects are a reduction of pain for about three hours after each dosage. I recommend this medication ( after FDA approval of course) to anyone struggling to find seizure control with other methods. My seizures dropped from 150 a month at the start of this med to under a dozen a month. Ordinarily I have to take a 90 minute nap after each dosage.
Cost: < $25 monthly

  • 0 helpful marks
Last updated:
Showing 1 of 1 patient evaluation for Epilepsy Phase 3 Study Retigabine IR